GlassScriptPhysician profile
Brianna E Brownlee
NPI 1578123915
$1,400.84
in general payments reported to CMS, 2019-2025
26 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $213 · 2024: $409 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.82 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $254.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $195.31 | 2022-2025 | |
| Abbvie INC. | $190.15 | 2023-2025 | Ubrelvy, Vraylar, Viberzi |
| Astellas Pharma US INC | $170.51 | 2024-2025 | Veozah |
| Amgen INC. | $77.20 | 2022-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $60.83 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $41.06 | 2025 | Austedo Xr |
| Glaxosmithkline, LLC. | $40.15 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $39.18 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $37.44 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.94 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $27.95 | 2025 | Fanapt |
| Grifols USA, LLC | $23.40 | 2024 | Prolastin-C Liquid |
| Springworks Therapeutics, INC. | $23.30 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.07 | 2023 | Synjardy, Tradjenta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $22.89 | 2025 | Andembry |
| Actelion Pharmaceuticals US, INC. | $18.70 | 2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $16.46 | 2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $14.22 | 2024 | Voquezna |
| Exact Sciences Corporation | $14.18 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2024 | Eliquis |
| Collegium Pharmaceutical, INC. | $13.71 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $12.60 | 2022 | |
| Lilly USA, LLC | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Brownlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.